ImmTher

Drug Profile

ImmTher

Latest Information Update: 28 Aug 2007

Price : $50

At a glance

  • Originator DOR BioPharma
  • Class Antineoplastics; Phosphatidylcholines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bone cancer; Colorectal cancer; Malignant melanoma; Prostate cancer

Most Recent Events

  • 17 Sep 1998 Endorex received a Japanese patent for ImmTher
  • 30 Jun 1998 ImmTher has Orphan Drug status for the treatment of Ewing's sarcoma in the US
  • 18 Mar 1998 Phase-II clinical trials for Bone cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top